Keeping Track: US FDA Clears Kisqali For Breast Cancer And Keytruda In Lymphoma, But Turns Down AZ's ZS-9 Again
Executive Summary
The latest drug development news and highlights from our FDA Performance Tracker.
You may also be interested in...
Keeping Track: Immuno-Oncology Racks Up More Approvals; Bar Still Too High For Advair Generics
The latest drug development news and highlights from our US FDA Performance Tracker.
FDA's NDA And BLA Approvals: Kisqali, Voriconazole
Original new drugs and biologics recently approved by US FDA.
US FDA Strategy On Abuse-Deterrent Opioids Needs Rethinking, Panelists Say
Deterring intravenous abuse over other routes of abuse should be agency's priority, some advisory committee members say during discussion of abuse patterns and risks with Endo’s reformulated Opana ER.